Non-Homologous DNA End Joining in Anticancer Therapy

Elzbieta Pastwa; Mariusz Malinowski

doi:10.2174/156800907780618284

ISSN: 1568-0096
E-ISSN: 1873-5576

Non-Homologous DNA End Joining in Anticancer Therapy
Authors: Elzbieta Pastwa¹ and Mariusz Malinowski²
View Affiliations Hide Affiliations

¹ Molecular Genetics Department,Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. ² Molecular Genetics Department,Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Source: Current Cancer Drug Targets, Volume 7, Issue 3, May 2007, p. 243 - 250
DOI: https://doi.org/10.2174/156800907780618284
- Available online: 01 May 2007

Abstract

Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become molecular targets in the treatment of cancer. Inhibition of this pathway leads to radio- and chemosensitization of cancer cells. This review will focus on the new therapeutic strategies for NHEJ pathway inhibition and their application in anticancer therapy.

Article metrics loading...

/content/journals/ccdt/10.2174/156800907780618284

2007-05-01

2025-09-05

From This Site

/content/journals/ccdt/10.2174/156800907780618284

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/content/journals/ccdt/10.2174/156800907780618284

Article Type: Research Article

Keyword(s): chemosensitization; DNA double-strand breaks; DNA-dependent protein kinase; DNA-PK; DSBs; NHEJ; Non-homologous DNA end joining; radiosensitization

Most Cited Most Cited RSS feed

- Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
  
  Authors: Yong Lin, Ranxin Shi, Xia Wang and Han-Ming Shen
- The Role of Snail in EMT and Tumorigenesis
  
  Authors: Yifan Wang, Jian Shi, Kequn Chai, Xuhua Ying and Binhua P. Zhou
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
  
  Authors: Amancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, Wolfgang Link and Juan F.M. Leal
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
  
  Authors: D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
  
  Authors: Ziyad Binkhathlan and Afsaneh Lavasanifar
- Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
  
  Authors: M. Abal, J.M. Andreu and I. Barasoain
- Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
  
  Authors: R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson and M.V. Seiden
- The Role of Fibroblast Growth Factors in Tumor Growth
  
  Authors: M. Korc and R. E. Friesel
- Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
  
  Authors: M. Thomson and M. Ali
- Oxidative Stress and Cancer: The Role of Nrf2
  
  Authors: Soraya Sajadimajd and Mozafar Khazaei
More Less

Non-Homologous DNA End Joining in Anticancer Therapy

Abstract

Most Read This Month

Most Cited Most Cited RSS feed